Following the viewing of the educational film, there was a modest increase in the prescription rates for nirmatrelvir/ritonavir, from 10.9% to 14.8% in case 9 (hypertension or hyperlipidemia, vaccinated, and no CYP3A-metabolized drugs) and 12.7% to 22.5% in case 11 (hypertension or hyperlipidemia, unvaccinated, and no CYP3A-metabolized drugs). This evidence concerns the gene CYP3A4 and hyperlipidemia.